<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 5 -->
<!-- Creation date: 2014-05-12T13:27:25Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:cara="http://www.caratherapeutics.com/20140331" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="cara-20140331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140205_0" unitRef="shares" decimals="INF" id="id_4942281_BC1B012E-9BDF-4598-AC2D-334FCD1A827A_1002_3">29186929</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20140205_0" unitRef="shares" decimals="INF" id="id_4942281_BC1B012E-9BDF-4598-AC2D-334FCD1A827A_1002_2">29186929</us-gaap:TemporaryEquitySharesIssued>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140505_0" unitRef="shares" decimals="INF" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_2_5">22601997</dei:EntityCommonStockSharesOutstanding>
  <cara:DeferredLicenseFee contextRef="eol_PE693401--1410-Q0003_STD_0_20130430_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_D3152EDD-0D5A-4CDE-89AB-AE5459BC5BAB_1_0">15000000</cara:DeferredLicenseFee>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_3005_8">-55267000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1002_21">690000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x924725" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_3003_7">2411000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_3004_8">-61125000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_3001_9">4288243</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_3001_8">4000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x932377" unitRef="shares" decimals="INF" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_3001_8">24389375</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x932377" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_3001_7">54056000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_3003_8">5854000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_32">22592414</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_18">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_F9D2B848-3473-4E90-98DF-D2FD0F93AE1C_1001_3">476660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_20">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_31">22592414</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_27">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_28E582AA-A5F5-4F54-A33B-3766CF53C463_1001_2">5.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_F9D2B848-3473-4E90-98DF-D2FD0F93AE1C_1001_2">877160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_17">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_7005_16">11.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_25">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_28E582AA-A5F5-4F54-A33B-3766CF53C463_1001_3">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_30">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_19">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_29">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_24">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_26">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_23" />
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_21">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_4">1692000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_1_4">22000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_33">130544000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_1_0">1586000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_1_2">192000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_13">5753000</us-gaap:LiabilitiesCurrent>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_2">1838000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_5">952000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_35">64728000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_1_3">104000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_6" />
  <us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_1">1812000</us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear>
  <us-gaap:ContractualObligation contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_7">8159000</us-gaap:ContractualObligation>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_11">2336000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_34">-65839000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_12">3417000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_14">1074000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_28">23000</us-gaap:CommonStockValue>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1003_3">1865000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_15" />
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_7">700000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_1_1">580000</us-gaap:PrepaidInsurance>
  <us-gaap:AssetsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_5">68226000</us-gaap:AssetsCurrent>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_3">46000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:Assets contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_8">71555000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_2">67038000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_1_3">13000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_4">1142000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_6">2629000</us-gaap:PropertyPlantAndEquipmentNet>
  <cara:NumberOfExecutiveOfficers contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="Officers" decimals="INF" id="id_4942281_1F3A7AF4-0739-468C-9716-783445DD7409_1001_0">3</cara:NumberOfExecutiveOfficers>
  <cara:StockholderEquityReverseStockSplitEffectiveDate contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" id="id_4942281_BBA39616-3969-4E33-8D51-B0835B5051AC_1001_2">2014-01-16</cara:StockholderEquityReverseStockSplitEffectiveDate>
  <cara:PrepaidResearchAndDevelopmentExpenses contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_1_2">549000</cara:PrepaidResearchAndDevelopmentExpenses>
  <cara:CompletionDateOfInitialPublicOffering contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" id="id_4942281_BC1B012E-9BDF-4598-AC2D-334FCD1A827A_1001_5">2014-02-05</cara:CompletionDateOfInitialPublicOffering>
  <cara:AccruedResearchProjects contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_1_1">432000</cara:AccruedResearchProjects>
  <cara:LiabilitiesConvertiblePreferredStockAndStockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_1_36">71555000</cara:LiabilitiesConvertiblePreferredStockAndStockholdersEquity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926437x923140_930809x1258850" unitRef="shares" decimals="INF" id="id_4942281_CA22B231-5575-488C-85B5-1C6D9EDC4953_2001_1">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_4">952000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_2">952000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_5">952000</us-gaap:ContractualObligationDueInFifthYear>
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_6" />
  <us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_1">952000</us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear>
  <us-gaap:ContractualObligation contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_7">4760000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1002_3">952000</us-gaap:ContractualObligationDueInThirdYear>
  <us-gaap:ContractualObligationDueInFourthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_4">740000</us-gaap:ContractualObligationDueInFourthYear>
  <us-gaap:ContractualObligationDueInSecondYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_2">886000</us-gaap:ContractualObligationDueInSecondYear>
  <us-gaap:ContractualObligationDueInFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_5" />
  <us-gaap:ContractualObligationDueAfterFifthYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_6" />
  <us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_1">860000</us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear>
  <us-gaap:ContractualObligation contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_7">3399000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInThirdYear contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542" unitRef="iso4217_USD" decimals="-3" id="id_4942281_97BA1BC4-4291-45A5-8671-8EE432DB7F17_1001_3">913000</us-gaap:ContractualObligationDueInThirdYear>
  <cara:RestrictedCashFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926956x927254_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_1001_2">700000</cara:RestrictedCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_926956x932359_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_2001_1">67038000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x924725" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_7003_13" />
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_7004_20">-65839000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_7001_21">22592414</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_7001_20">23000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x932377" unitRef="shares" xsi:nil="true" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_7001_14" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x932377" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_7001_13" />
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_7003_20">130544000</us-gaap:StockholdersEquity>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_1_3">67738000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_930809x1083036" unitRef="shares" decimals="INF" id="id_4942281_E0E84B86-2B6B-4C8E-BC9F-CFF3ABF4F684_1002_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140331_0_930809x1258850" unitRef="shares" decimals="INF" id="id_4942281_CA22B231-5575-488C-85B5-1C6D9EDC4953_1001_0">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_1005_1">-58133000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2001_20">1117000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x924725" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_1003_1">2050000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_1004_1">-59384000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_1001_2">3328698</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_1001_1">3000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x932377" unitRef="shares" decimals="INF" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_1001_2">26636118</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x932377" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_1001_1">58522000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_1003_1">1248000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_32">4288243</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_18">29402200</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_20">29186929</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_31">4288243</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_27">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_28E582AA-A5F5-4F54-A33B-3766CF53C463_2001_0">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_F9D2B848-3473-4E90-98DF-D2FD0F93AE1C_2001_0">490160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_17">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_25">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_30">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_19">29186929</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_29">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_24">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_26">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_23" />
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_21">65969000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_2_4">55000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_33">8377000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_2_0">676000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_2_2">739000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_13">5433000</us-gaap:LiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_35">-54075000</us-gaap:StockholdersEquity>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_2_3">83000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_16">65586000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_11">1958000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_34">-62456000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_12">3475000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_14">1139000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_28">4000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_15" />
  <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_7">700000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_2_1">34000</us-gaap:PrepaidInsurance>
  <us-gaap:AssetsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_5">14558000</us-gaap:AssetsCurrent>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_3">61000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:Assets contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_8">18083000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_2">12357000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_2_3">11000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_4">2140000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_6">2825000</us-gaap:PropertyPlantAndEquipmentNet>
  <cara:PrepaidInitialPublicOfferingCosts contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_2_4">1833000</cara:PrepaidInitialPublicOfferingCosts>
  <cara:PrepaidResearchAndDevelopmentExpenses contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_1A48B0E2-B74F-46BB-B1D1-B33AB4516A52_2_2">262000</cara:PrepaidResearchAndDevelopmentExpenses>
  <cara:AccruedResearchProjects contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8600A2D5-8302-420F-9853-E56D6B51E9A9_2_1">405000</cara:AccruedResearchProjects>
  <cara:LiabilitiesConvertiblePreferredStockAndStockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_9849D313-9EB4-4D8A-8DFE-FA10FE62663D_2_36">18083000</cara:LiabilitiesConvertiblePreferredStockAndStockholdersEquity>
  <cara:RestrictedCashFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_926956x927254_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_1002_2">700000</cara:RestrictedCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_926956x932359_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_2002_1">12357000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x924725" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_5003_9" />
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_5004_10">-62456000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_5001_11">4288243</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_5001_10">4000</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x932377" unitRef="shares" decimals="INF" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_5001_10">29186929</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x932377" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_5001_9">65586000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_5003_10">8377000</us-gaap:StockholdersEquity>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_928472x926284_929790x925736" unitRef="iso4217_USD" decimals="-3" id="id_4942281_4B8462C8-FF94-411C-8157-93C7E4C2A4AC_2_3">13057000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_930809x1083036" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_E0E84B86-2B6B-4C8E-BC9F-CFF3ABF4F684_1001_1">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_930809x1083036" unitRef="shares" decimals="INF" id="id_4942281_E0E84B86-2B6B-4C8E-BC9F-CFF3ABF4F684_1001_0">490160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE693401--1410-Q0003_STD_0_20131231_0_930809x1083036" unitRef="shares" decimals="INF" id="id_4942281_E0E84B86-2B6B-4C8E-BC9F-CFF3ABF4F684_1001_2">757799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140116_0" unitRef="shares" decimals="INF" id="id_4942281_92081BE6-EFCF-4B0F-98B9-BE489AE0AD37_1_3">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE693401--1410-Q0003_STD_0_20140116_0" unitRef="shares" decimals="INF" id="id_4942281_92081BE6-EFCF-4B0F-98B9-BE489AE0AD37_1_0">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140116_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_92081BE6-EFCF-4B0F-98B9-BE489AE0AD37_1_2">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140116_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_92081BE6-EFCF-4B0F-98B9-BE489AE0AD37_1_4">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE693401--1410-Q0003_STD_0_20140130_0" unitRef="shares" decimals="INF" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_1_0">5750000</us-gaap:CommonStockSharesIssued>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE693401--1410-Q0003_STD_0_20140130_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_1_2">11.00</us-gaap:SharesIssuedPricePerShare>
  <cara:CommonStockSharesIssuedUponExerciseByUnderwriters contextRef="eol_PE693401--1410-Q0003_STD_0_20140130_0" unitRef="shares" decimals="INF" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_1_1">750000</cara:CommonStockSharesIssuedUponExerciseByUnderwriters>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="eol_PE693401--1410-Q0003_STD_2_20140205_0" unitRef="shares" decimals="INF" id="id_4942281_BC1B012E-9BDF-4598-AC2D-334FCD1A827A_2_4">12554171</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE693401--1410-Q0003_STD_2_20140331_0" unitRef="pure" decimals="1" id="id_4942281_BBA39616-3969-4E33-8D51-B0835B5051AC_1_1">2.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <cara:OfferingExpenses contextRef="eol_PE693401--1410-Q0003_STD_2_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_3_6">2576000</cara:OfferingExpenses>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE693401--1410-Q0003_STD_2_20140130_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_2_3">63250000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <cara:UnderwritingDiscountsAndCommissions contextRef="eol_PE693401--1410-Q0003_STD_2_20140130_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_2_5">4427000</cara:UnderwritingDiscountsAndCommissions>
  <cara:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid contextRef="eol_PE693401--1410-Q0003_STD_2_20140130_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_81DDB104-28A0-41A7-9E7D-AE8E6246EFB4_2_4">56247000</cara:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid>
  <cara:ProceedsFromIssuanceOfDebtAndEquityFinancingPriorToInitialPublicOffering contextRef="eol_PE693401--1410-Q0003_STD_365_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_8CB83CAE-412E-45EA-99F7-C4255EFC5803_1_0">73309000</cara:ProceedsFromIssuanceOfDebtAndEquityFinancingPriorToInitialPublicOffering>
  <cara:AnnualIncreaseInNumberOfSharesReservedForIssuanceAsPercentageOfSharesOfCapitalStockOutstanding contextRef="eol_PE693401--1410-Q0003_STD_365_20131231_0_930809x1258850" unitRef="pure" decimals="INF" id="id_4942281_CA22B231-5575-488C-85B5-1C6D9EDC4953_1002_2">0.03</cara:AnnualIncreaseInNumberOfSharesReservedForIssuanceAsPercentageOfSharesOfCapitalStockOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" decimals="0" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_8">3659208</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_6" />
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_7" />
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" decimals="0" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_17">3659208</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_13">-1819000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_5" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_4942281_AA1D40FC-76E5-4C5D-9429-1753ABDE340E_2_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" decimals="0" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_1">3659208</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_2_4" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_2_4">12338677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Revenues contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_2" />
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_10">66000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:PaymentsOfFinancingCosts contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_16">70000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_9">-2639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_9">7000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_8">-1129000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4005_5">1021000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_7">-1510000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_11">-2632000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_11">-386000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_5">588000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_18">1392000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4005_3">4466000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4005_6">-11000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_19">-427000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_4">922000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_5">198000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_7">19000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_15">1462000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:OperatingExpenses contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_6">1510000</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_10">-7000</us-gaap:IncomeTaxExpenseBenefit>
  <cara:CollaborativeRevenue contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_1" />
  <cara:NonCashCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_3">11000</cara:NonCashCompensationExpense>
  <cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_13">-1741000</cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <cara:DeferredRentLiabilityBenefit contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_6">59000</cara:DeferredRentLiabilityBenefit>
  <cara:AccruedInterestAndAmortizationOfBeneficialConversionFeatureOnPromissoryNotes contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_2_4">1103000</cara:AccruedInterestAndAmortizationOfBeneficialConversionFeatureOnPromissoryNotes>
  <cara:ExtinguishmentOfPreferredStock contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_960E0978-23A0-4ED7-849C-6F85AC452022_2_1">891000</cara:ExtinguishmentOfPreferredStock>
  <cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_2_15">-0.48</cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x924725" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_4003_6">-1021000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <cara:BeneficialConversionFeatureConvertiblePromissoryNotes contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x924725" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_4003_5">1382000</cara:BeneficialConversionFeatureConvertiblePromissoryNotes>
  <us-gaap:NetIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4004_7">-2632000</us-gaap:NetIncomeLoss>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4004_3">891000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4001_4">959545</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4001_3">1000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932377" unitRef="shares" decimals="INF" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_4001_4">-2246743</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932377" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_4001_3">-4466000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4003_5">1021000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4003_3">3574000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_4003_6">-11000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x926173" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_1002_3">1126517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x926520" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_2002_1">557160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x929614" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_3002_2">19851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x932377" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_4002_0">10635149</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_929038x1252239" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0C026780-9380-40CB-8732-7EF7BBE9CF17_1002_0">9000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20130331_0_929038x975410" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0C026780-9380-40CB-8732-7EF7BBE9CF17_2002_1">2000</us-gaap:AllocatedShareBasedCompensationExpense>
  <dei:TradingSymbol contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_1_0">CARA</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_1_1">Cara Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_B4E8DCC9-5131-4834-8C30-EE89F10BDEEA_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_B4E8DCC9-5131-4834-8C30-EE89F10BDEEA_1_3">2014</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_B4E8DCC9-5131-4834-8C30-EE89F10BDEEA_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_B4E8DCC9-5131-4834-8C30-EE89F10BDEEA_1_2">2014-03-31</dei:DocumentPeriodEndDate>
  <dei:EntityIncorporationDateOfIncorporation contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_C5BA639A-C51C-4967-B209-B322EA43A20C_1_0">2004-07-02</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityCentralIndexKey contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_1_2">0001346830</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_6ECF2E7B-4550-4E01-8201-FAA78C2B3560_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_B4E8DCC9-5131-4834-8C30-EE89F10BDEEA_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_228FE306-7FC1-4760-93AC-0FB394C7BEBE_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Stock Based Compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 6%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;2014 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company&amp;#x2019;s Board of Directors adopted, and its
 stockholders subsequently approved, its 2014 Equity Incentive Plan
 (the &amp;#x201C;2014 Plan&amp;#x201D;) in January 2014. The 2014 Plan became
 effective immediately upon the signing of the underwriting
 agreement for the Company&amp;#x2019;s initial public offering. The 2014
 Plan is administered by the Company&amp;#x2019;s Board of Directors or a
 duly authorized committee thereof (the &amp;#x201C;Plan
 administrator&amp;#x201D;). The 2014 Plan provides for the grant of
 incentive stock options, non-statutory stock options, restricted
 stock awards, restricted stock unit awards, stock appreciation
 rights, performance stock awards and other forms of equity
 compensation (collectively, &amp;#x201C;Stock Awards&amp;#x201D;).
 Additionally, the 2014 Plan provides for the grant of performance
 cash awards. Incentive stock options may be granted only to
 employees. All other awards may be granted to employees, including
 officers, non-employee directors, and consultants. No incentive
 stock options may be granted under the 2014 Plan after the tenth
 anniversary of the effective date of the 2014 Plan. Stock Awards
 granted under the 2014 Plan vest at the rate specified by the Plan
 administrator. The Plan administrator determines the term of Stock
 Awards granted under the 2014 Plan up to a maximum of ten
 years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Initially, the aggregate number of shares of the Company&amp;#x2019;s
 common stock that may be issued pursuant to Stock Awards under the
 2014 Plan is 1,600,000 shares. Additionally, the number of shares
 of the Company&amp;#x2019;s common stock reserved for issuance under the
 2014 Plan will automatically increase on January&amp;#xA0;1 of each
 year, beginning on January&amp;#xA0;1, 2015 and continuing through and
 including January&amp;#xA0;1, 2024, by 3% of the total number of shares
 of the Company&amp;#x2019;s capital stock outstanding on
 December&amp;#xA0;31 of the preceding calendar year, or a lesser number
 of shares determined by the Company&amp;#x2019;s Board of Directors. The
 maximum number of shares that may be issued pursuant to the
 exercise of incentive stock options under the 2014 Plan is
 30,000,000 shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 6%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;2004 Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Under the 2004 Stock Incentive Plan (&amp;#x201C;2004 Plan&amp;#x201D;), the
 Company has granted stock options to selected officers, employees
 and consultants of the Company. As of December&amp;#xA0;31 2013,
 options to purchase 490,160 shares of common stock were outstanding
 under the 2004 Plan, with a weighted average exercise price per
 share of $1.34. Although as of December&amp;#xA0;31 2013, 757,799
 shares remained available for future issuance pursuant to the grant
 of options or restricted share awards under the 2004 Plan,
 following the effectiveness of the 2014 Plan in January 2014, no
 additional options or restricted share awards have been or will be
 granted under the 2004 Plan. The 2014 Plan and 2004 Plan are
 referred to collectively as the Stock Incentive Plans.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Under the Stock Incentive Plans, the Company granted 387,000 stock
 options during the three months ended March&amp;#xA0;31, 2014 and no
 stock options during the three months ended March&amp;#xA0;31, 2013.
 The fair value of stock options granted during the three months
 ended March&amp;#xA0;31, 2014 was estimated as of the date of grant
 using the Black-Scholes option pricing model with the following
 assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="21%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 2.19%&amp;#xA0;-&amp;#xA0;2.72%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 67%&amp;#xA0;-&amp;#xA0;71%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of employee options (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of nonemployee options (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;20%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average grant-date fair value (employees and
 directors)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;$6.88&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 During the three months ended March&amp;#xA0;31, 2014 and
 March&amp;#xA0;31, 2013, the Company recognized compensation expense
 relating to stock options issued to employees and nonemployee
 directors for their service on the Board of Directors of $219 and
 $9, respectively. During the three months ended March&amp;#xA0;31, 2014
 and March&amp;#xA0;31, 2013, the Company recognized compensation
 expense relating to stock options issued to non-employee
 consultants of $134 and $2, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of stock option award activity under the Company&amp;#x2019;s
 Stock Incentive Plans as of and for the three months ended
 March&amp;#xA0;31, 2014 is presented below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;490,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable, March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;476,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_AFBEC249-93B9-4E6A-B960-1BE57C14B523_1_0">&lt;div&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table width="76%" align="center" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td width="12%" valign="bottom"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td width="12%" valign="bottom"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 8pt;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td align="center" valign="bottom" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td align="center" valign="bottom" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;1,586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;676&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;432&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;405&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;192&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;739&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;104&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;83&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;55&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size: 1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 3em;"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;2,336&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;1,958&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size: 1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_5E88BF4F-56DE-4BAD-9465-1923C0558634_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Contractual obligations and commitments as of March&amp;#xA0;31, 2014
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;Payment Due for the Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Thereafter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;913&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;740&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,399&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employment agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,159&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company leases its operating facility located in Shelton
 Connecticut.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Effective January 2014, the Company entered into employment
 agreements with three of its executive officers. Each such
 employment agreement has a term of four years and is renewable on
 the same terms for one additional year unless the executive officer
 party to such agreement notifies the Company in writing not to
 renew. Under these employment agreements, each executive officer is
 eligible for severance benefits in specified circumstances,
 including 6 months to 12 months of salary.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_991A1EA2-024B-41D3-A824-BA77668B20C0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company records revenue related to these agreements in
 accordance with ASC 605-25, &lt;i&gt;Revenue Recognition Multiple-Element
 Arrangements&lt;/i&gt;. In order to account for these agreements, the
 Company identifies the deliverables included within the arrangement
 and evaluates which deliverables represent separate units of
 accounting based on whether certain criteria are met, including
 whether the delivered element has stand-alone value to the
 counterparty. The consideration received is then allocated among
 the separate units of accounting based on each unit&amp;#x2019;s
 relative selling price. The identification of individual elements
 in a multiple-element arrangement and the estimation of the selling
 price of each element involve significant judgment, including
 consideration as to whether each delivered element has standalone
 value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_8">15654079</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_DAD06907-E432-4D84-81C0-A31F8955E92A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 A summary of stock option award activity under the Company&amp;#x2019;s
 Stock Incentive Plans as of and for the three months ended
 March&amp;#xA0;31, 2014 is presented below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;490,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.60&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options exercisable, March&amp;#xA0;31, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;476,660&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.55&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_6" />
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_BBA39616-3969-4E33-8D51-B0835B5051AC_2_0">The Company&apos;s Board of Directors and stockholders approved a 1-for-2.5 reverse  stock split of the Company&apos;s common stock effective on January 16, 2014, which  resulted in an adjustment to the preferred stock conversion price to reflect a  proportional decrease in the number of shares of common stock to be issued upon  conversion.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:NatureOfOperations contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_8D2598F9-4440-425F-98A6-C68EFFAECACA_1_0">&lt;div&gt;
 &lt;table width="100%" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="4%" align="left" valign="top"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Business&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 Cara Therapeutics, Inc. (the &amp;#x201C;Company&amp;#x201D;,
 &amp;#x201C;we&amp;#x201D;, &amp;#x201C;our&amp;#x201D; or &amp;#x201C;us&amp;#x201D;) is a
 clinical-stage biopharmaceutical corporation formed on July&amp;#xA0;2,
 2004. The Company is focused on developing and commercializing new
 chemical entities designed to alleviate pain by selectively
 targeting kappa opioid receptors. Our primary activities to date
 have been organizing and staffing our company, developing our
 product candidates, including conducting preclinical studies and
 clinical trials of CR845-based product candidates and raising
 capital.&lt;/p&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;
 On January&amp;#xA0;30, 2014, the Company&amp;#x2019;s registration
 statement on Form S-1 (File No 333-192230) was declared effective
 by the Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;) for
 its initial public offering (&amp;#x201C;IPO&amp;#x201D;), pursuant to which
 the Company registered the offering and sale of 5,750,000 shares of
 common stock (including 750,000 shares upon exercise of an option
 by the underwriters) at a public offering price of $11.00 per share
 for an aggregate offering price of $63,250. As a result of the IPO,
 the Company received net proceeds of approximately $56,247 from the
 sale of 5,750,000 shares of common stock, after deducting $4,427 of
 underwriting discounts and commissions and $2,576 of offering
 expenses, which had been paid or accrued as of March&amp;#xA0;31,
 2014.&lt;/p&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;
 Prior to the IPO, the Company raised several rounds of equity
 financing and issued debt, resulting in aggregate net proceeds of
 approximately $73,309 through December&amp;#xA0;31, 2013. Upon closing
 of the IPO, all shares of the Company&amp;#x2019;s convertible preferred
 stock were automatically converted to shares of common stock (see
 Note 8). The Company has incurred substantial losses and negative
 cash flows from operating activities in nearly every fiscal period
 since inception, and expects operating losses and negative cash
 flows to continue into the foreseeable future.&lt;/p&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;
 As of March&amp;#xA0;31, 2014, the Company has unrestricted cash and
 cash equivalents of $67,038 and an accumulated deficit of $65,839.
 The Company had net cash used in operating activities of $3,091 and
 $1,819 for the three months ended March&amp;#xA0;31, 2014 and
 March&amp;#xA0;31, 2013, respectively. The Company expects that cash
 and cash equivalents at March&amp;#xA0;31, 2014 will be sufficient to
 fund its operations beyond one year. The Company recognized net
 losses of $3,383 and $2,632 for the three months ended
 March&amp;#xA0;31, 2014 and March&amp;#xA0;31, 2013, respectively, and
 expects to incur additional losses for the full year ending
 December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;
 The Company is subject to risks common to other life science
 companies including, but not limited to, uncertainty of product
 development and commercialization, lack of marketing and sales
 history, development by its competitors of new technological
 innovations, dependence on key personnel, market acceptance of
 products, product liability protection of proprietary technology,
 ability to raise additional financing, and compliance with Food and
 Drug Administration (&amp;#x201C;FDA&amp;#x201D;) and other government
 regulations. If the Company does not successfully commercialize any
 of its product candidates, it will be unable to generate recurring
 product revenue or achieve profitability.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_7627F41B-1250-46FB-9B68-851143B926C5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Securities outstanding at the end of the respective periods
 presented below, that could potentially dilute basic earnings per
 share in the future, that were not included in the computation of
 diluted net loss per share because to do so would have been
 antidilutive are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,635,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;557,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible promissory notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,126,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;897,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,338,677&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_7" />
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_4A45F2C2-027B-47EC-AA9B-167DB8CCF915_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013, the
 Company&amp;#x2019;s financial instruments consist of cash and cash
 equivalents, restricted cash, accounts payable and accrued
 liabilities. The carrying amount of each of those financial
 instruments are generally considered to be representative of their
 respective fair values because of the short-term nature of those
 instruments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Current accounting guidance defines fair value, establishes a
 framework for measuring fair value in accordance with Accounting
 Standards Codification (&amp;#x201C;ASC&amp;#x201D;) section 820, and
 requires certain disclosures about fair value measurements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The valuation techniques included in the guidance are based on
 observable and unobservable inputs. Observable inputs reflect
 readily obtainable data from independent sources, while
 unobservable inputs reflect market assumptions and are classified
 into the following fair value hierarchy:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 Level&amp;#xA0;1&amp;#xA0;&amp;#x2013;&amp;#xA0;Observable inputs&amp;#xA0;&amp;#x2013;
 quoted prices in active markets for identical assets and
 liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 Level&amp;#xA0;2&amp;#xA0;&amp;#x2013;&amp;#xA0;Observable inputs other than the
 quoted prices in active markets for identical assets and
 liabilities&amp;#xA0;&amp;#x2013; such as quoted prices for similar
 instruments, quoted prices for identical or similar instruments in
 inactive markets, or other inputs that are observable or can be
 corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 Level&amp;#xA0;3&amp;#xA0;&amp;#x2013;&amp;#xA0;Unobservable inputs&amp;#xA0;&amp;#x2013;
 includes amounts derived from valuation models where one or more
 significant inputs are unobservable and require the company to
 develop relevant assumptions.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the financial assets measured at
 fair value on a recurring basis as of March&amp;#xA0;31, 2014 and
 December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Financial assets&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,038&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted cash:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Bank certificate of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,738&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_0F5AFE03-B618-4EDE-8DD8-79C6471BE16F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the financial assets measured at
 fair value on a recurring basis as of March&amp;#xA0;31, 2014 and
 December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Financial assets&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Cash equivalents:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,038&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Restricted cash:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Bank certificate of deposit&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;700&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67,738&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_BE87D4C9-5710-463F-A434-C76BAF4BCD86_1_0">&lt;div&gt;
 &lt;table width="100%" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="4%" align="left" valign="top"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Accounts Payable and Accrued
 Expenses&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table width="76%" align="center" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td width="12%" valign="bottom"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td width="12%" valign="bottom"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 8pt;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td align="center" valign="bottom" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td align="center" valign="bottom" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;1,586&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;676&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;432&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;405&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued professional fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;192&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;739&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued compensation and benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;104&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;83&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 1em;"&gt;
 Accrued other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;55&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size: 1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 1px; border-top-style: solid;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family: Times New Roman; font-size: 10pt;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-left: 3em;"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;2,336&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td align="right" valign="bottom"&gt;1,958&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size: 1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top-color: rgb(0, 0, 0); border-top-width: 3px; border-top-style: double;"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_17">15654079</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_2A1689C3-5E75-4D04-B683-34A28080BB6C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Basic and diluted net loss per share attributable to common
 stockholders are computed as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,632&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Add back: extinguishment of preferred shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders - Basic and
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,741&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted-average common shares outstanding attributable to common
 stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_9F337392-0FF1-419A-8521-4269663AE7C1_1_0">&lt;div&gt;
 &lt;table width="100%" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="4%" align="left" valign="top"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Stockholders&amp;#x2019; (Deficit)
 Equity&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 On January&amp;#xA0;16, 2014, the Company&amp;#x2019;s Board of Directors
 approved an Amended and Restated Certificate of Incorporation,
 which, among other things, increased the authorized number of
 shares of the Company&amp;#x2019;s common stock, par value $0.001 per
 share, from 50,000,000 to 100,000,000 and authorized 5,000,000
 shares of undesignated preferred stock, par value $0.001 per share,
 that may be issued from time to time by the Board of Directors of
 the Company in one or more series. As of March&amp;#xA0;31, 2014, there
 were 22,592,414 shares of common stock and no shares of preferred
 stock issued and outstanding.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_28E582AA-A5F5-4F54-A33B-3766CF53C463_1_1">11.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_13">-3091000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_5" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_3_6">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="pure" decimals="2" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_3_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_AA1D40FC-76E5-4C5D-9429-1753ABDE340E_1_0">387000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_99C7E320-3B72-4E37-B605-DC6B512F1035_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying unaudited interim Condensed Financial Statements
 included herein have been prepared pursuant to the rules and
 regulations of the SEC. Accordingly, they do not include all
 information and disclosures necessary for a presentation of the
 Company&amp;#x2019;s financial position, results of operations and cash
 flows in conformity with generally accepted accounting principles
 in the United States of America (&amp;#x201C;GAAP&amp;#x201D;). In the
 opinion of management, these unaudited interim financial statements
 reflect all adjustments, consisting primarily of normal recurring
 accruals, necessary for a fair presentation of results for the
 periods presented. The results of operations for interim periods
 are not necessarily indicative of the results for the full year.
 Certain information and footnote disclosures normally included in
 financial statements prepared in accordance with GAAP have been
 condensed or omitted from this report, as is permitted by SEC rules
 and regulations; however, the Company believes that the disclosures
 are adequate to make the information presented not misleading. The
 condensed balance sheet data for the year ended December&amp;#xA0;31,
 2013 were derived from audited financial statements, but do not
 include all disclosures required by GAAP. These unaudited interim
 condensed financial statements should be read in conjunction with
 the audited financial statements and accompanying notes thereto
 included in the Company&amp;#x2019;s Annual Report on Form 10-K for the
 year ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with GAAP
 requires the Company to make estimates and assumptions that affect
 the reported amounts of assets and liabilities, and disclosure of
 contingent assets and liabilities, as of the date of the financial
 statements as well as the reported amounts of revenues and expenses
 during the reporting period. Actual results could differ materially
 from the Company&amp;#x2019;s estimates and assumptions. Significant
 estimates include useful lives of fixed assets, the periods over
 which certain revenues will be recognized, including licensing and
 collaborative revenue recognized from non-refundable up-front
 payments, the amount of non-cash compensation costs related to
 share-based payments to employees and non-employees and the periods
 over which those costs are expensed and the likelihood of
 realization of deferred tax assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There have been no material changes to the significant accounting
 policies previously disclosed in Note 2 to the Financial Statements
 in the Company&amp;#x2019;s Annual Report on Form 10-K for the year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" decimals="0" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_1">15654079</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_D7EE3DA5-F3CF-4ECD-8D17-7542FF64A8E8_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the three months ended March&amp;#xA0;31, 2014 and 2013 pre-tax
 losses were $3,399 and $2,639, respectively. The Company recognized
 a full tax valuation allowance against deferred taxes at
 March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013. The benefit from
 income taxes of $16 and $7 for the three months ended
 March&amp;#xA0;31, 2014 and 2013, respectively, relates to state
 research and development tax credits exchanged for cash pursuant to
 the Connecticut Research and Development Tax Credit Exchange
 Program, which permits qualified small businesses engaged in
 research and development activities within Connecticut to exchange
 their unused research and development tax credits for a cash amount
 equal to 65% of the value of the exchanged credits.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_941C97C9-5D71-4E38-BE4E-58232863A633_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The accompanying unaudited interim Condensed Financial Statements
 included herein have been prepared pursuant to the rules and
 regulations of the SEC. Accordingly, they do not include all
 information and disclosures necessary for a presentation of the
 Company&amp;#x2019;s financial position, results of operations and cash
 flows in conformity with generally accepted accounting principles
 in the United States of America (&amp;#x201C;GAAP&amp;#x201D;). In the
 opinion of management, these unaudited interim financial statements
 reflect all adjustments, consisting primarily of normal recurring
 accruals, necessary for a fair presentation of results for the
 periods presented. The results of operations for interim periods
 are not necessarily indicative of the results for the full year.
 Certain information and footnote disclosures normally included in
 financial statements prepared in accordance with GAAP have been
 condensed or omitted from this report, as is permitted by SEC rules
 and regulations; however, the Company believes that the disclosures
 are adequate to make the information presented not misleading. The
 condensed balance sheet data for the year ended December&amp;#xA0;31,
 2013 were derived from audited financial statements, but do not
 include all disclosures required by GAAP. These unaudited interim
 condensed financial statements should be read in conjunction with
 the audited financial statements and accompanying notes thereto
 included in the Company&amp;#x2019;s Annual Report on Form 10-K for the
 year ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_A7AA3486-6A83-432C-8343-B1B203B201FE_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company computes basic net loss per share using the
 &amp;#x201C;two-class&amp;#x201D; method, which includes the weighted-average
 number of common stock outstanding during the period and other
 securities that participate in dividends (a participating
 security). Prior to the closing of the IPO, the Company&amp;#x2019;s
 shares of convertible preferred stock were participating securities
 as defined by ASC 260-10, Earnings Per Share. Under the two-class
 method, basic net earnings (loss) per share applicable to common
 stockholders is computed by dividing the net earnings (loss)
 applicable to common stockholders by the weighted-average number of
 common shares outstanding for the period. Diluted net earnings
 (loss) per share is computed using the more dilutive of
 (1)&amp;#xA0;the two-class method, or (2)&amp;#xA0;the
 &amp;#x201C;if-converted&amp;#x201D; method. The Company allocates net
 earnings on a pari passu (equal) basis to both common and preferred
 stockholders. Net losses are not allocated to preferred
 stockholders as they have no obligation to share in the
 Company&amp;#x2019;s net losses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Diluted net earnings (loss) per share gives effect to all
 potentially dilutive securities, including convertible preferred
 stock, convertible promissory notes and shares issuable upon the
 exercise of outstanding stock options and warrants, using the
 treasury stock method. For the three months ended March&amp;#xA0;31,
 2014 and 2013, the Company has excluded the effects of all
 potentially dilutive shares that were outstanding during those
 respective periods from the denominator as their inclusion would be
 ant-dilutive due to the Company&amp;#x2019;s net losses during those
 periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The denominators used in the net loss per share computations are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Convertible preferred stock*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Common stock options*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Common stock warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Convertible promissory notes (as if converted)*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator for diluted net loss per share available to common
 stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;No amounts were considered as their
 effects would be anti-dilutive.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Basic and diluted net loss per share attributable to common
 stockholders are computed as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,632&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Add back: extinguishment of preferred shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;891&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders - Basic and
 Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,383&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,741&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.22&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.48&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted-average common shares outstanding attributable to common
 stockholders:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Securities outstanding at the end of the respective periods
 presented below, that could potentially dilute basic earnings per
 share in the future, that were not included in the computation of
 diluted net loss per share because to do so would have been
 antidilutive are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible preferred stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,635,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;557,160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,851&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible promissory notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,126,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;897,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,338,677&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 All shares of the Company&amp;#x2019;s convertible preferred stock were
 automatically converted to shares of the Company&amp;#x2019;s common
 stock upon the closing of the IPO on February&amp;#xA0;5, 2014 (see
 Note 8). All convertible promissory notes were either converted
 into shares of the Company&amp;#x2019;s Series D convertible preferred
 stock or repaid in cash by December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" xsi:nil="true" id="id_4942281_AF59E84F-9192-4184-8866-1DE0CC5DA86E_1_4" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_1_4">897011</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:UseOfEstimates contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_2F4CC37C-1C44-4AC6-A068-A92363EE32B6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The preparation of financial statements in conformity with GAAP
 requires the Company to make estimates and assumptions that affect
 the reported amounts of assets and liabilities, and disclosure of
 contingent assets and liabilities, as of the date of the financial
 statements as well as the reported amounts of revenues and expenses
 during the reporting period. Actual results could differ materially
 from the Company&amp;#x2019;s estimates and assumptions. Significant
 estimates include useful lives of fixed assets, the periods over
 which certain revenues will be recognized, including licensing and
 collaborative revenue recognized from non-refundable up-front
 payments, the amount of non-cash compensation costs related to
 share-based payments to employees and non-employees and the periods
 over which those costs are expensed and the likelihood of
 realization of deferred tax assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 There have been no material changes to the significant accounting
 policies previously disclosed in Note 2 to the Financial Statements
 in the Company&amp;#x2019;s Annual Report on Form 10-K for the year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_CD059E11-51A8-42B1-8455-E0FE491F68F8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The fair value of stock options granted during the three months
 ended March&amp;#xA0;31, 2014 was estimated as of the date of grant
 using the Black-Scholes option pricing model with the following
 assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="21%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;March&amp;#xA0;31, 2014&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 2.19%&amp;#xA0;-&amp;#xA0;2.72%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="center"&gt;
 67%&amp;#xA0;-&amp;#xA0;71%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of employee options (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;6.25&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of nonemployee options (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;10&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;20%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Weighted average grant-date fair value (employees and
 directors)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;$6.88&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_BC1A7EA3-5CF6-480B-9F39-05D8360B779C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Contractual obligations and commitments as of March&amp;#xA0;31, 2014
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="18" align="center"&gt;&lt;b&gt;Payment Due for the Year Ending
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Thereafter&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Operating lease&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;913&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;740&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,399&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Employment agreements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,760&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,812&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,692&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,159&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
  <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_44A0F7BA-3166-4756-8D46-EA5FA0578FFE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The denominators used in the net loss per share computations are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Basic:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Convertible preferred stock*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Common stock options*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Common stock warrants*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2em; TEXT-INDENT: -1em"&gt;
 Convertible promissory notes (as if converted)*&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Denominator for diluted net loss per share available to common
 stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,654,079&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,659,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;No amounts were considered as their
 effects would be anti-dilutive.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
  <us-gaap:Revenues contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_2">178000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_10">377000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_9">-3399000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_9">-15000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_8">22000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_7">-3421000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_11">-3383000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9005_14">56247000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_11">227000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_5">1398000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_18">57772000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9005_12">65586000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_12">-58000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9005_18">-353000</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_19">54681000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_4">2201000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_5">197000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:OperatingExpenses contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_6">3599000</us-gaap:OperatingExpenses>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_10">-16000</us-gaap:IncomeTaxExpenseBenefit>
  <cara:EmploymentAgreementTerm contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_1F3A7AF4-0739-468C-9716-783445DD7409_1_1">P4Y</cara:EmploymentAgreementTerm>
  <cara:ConversionOfConvertiblePreferredStockIntoCommonStock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_23">65586000</cara:ConversionOfConvertiblePreferredStockIntoCommonStock>
  <cara:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_8AFA87D7-EFA8-4B70-97CD-D30E1695F6E3_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Prepaid expenses and other current
 assets&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014, prepaid expenses and other current
 assets was $1,142, consisting of $580 of prepaid insurance, $549 of
 research and development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) clinical costs and
 $13 of other costs. As of December&amp;#xA0;31, 2013, prepaid expenses
 and other current assets was $2,140, consisting of $1,833 of IPO
 costs, $262 of R&amp;amp;D clinical costs, $34 of prepaid insurance and
 $11 of other costs.&lt;/p&gt;
 &lt;/div&gt;</cara:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <cara:NumberOfMonthsSalaryPaidAsSeveranceBenefit contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_1F3A7AF4-0739-468C-9716-783445DD7409_1_3">Under these employment agreements, each executive officer is eligible for  severance benefits in specified circumstances, including 6 months to 12 months  of salary.</cara:NumberOfMonthsSalaryPaidAsSeveranceBenefit>
  <cara:ReverseStockSplitDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_F1A305BF-7E6A-4B4A-92A0-2E4702824FBC_1_0">&lt;div&gt;
 &lt;table width="100%" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="4%" align="left" valign="top"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 The Company&amp;#x2019;s Board of Directors and stockholders approved a
 1-for-2.5 reverse stock split of the Company&amp;#x2019;s common stock
 effective on January&amp;#xA0;16, 2014, which resulted in an adjustment
 to the preferred stock conversion price to reflect a proportional
 decrease in the number of shares of common stock to be issued upon
 conversion. All share and per share data in the interim unaudited
 financial statements and accompanying notes thereto included in
 this Quarterly Report on Form 10-Q have been retroactively adjusted
 for all periods presented to give effect to this reverse stock
 split.&lt;/p&gt;
 &lt;/div&gt;</cara:ReverseStockSplitDisclosureTextBlock>
  <cara:CollaborativeRevenue contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_1">178000</cara:CollaborativeRevenue>
  <cara:RevenueRecognitionTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_70129426-9774-4586-B1B0-34E71C44BAE5_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In general, the Company recognizes revenue when all of the
 following criteria are met: persuasive evidence of an arrangement
 exists; delivery has occurred or services have been rendered; the
 Company&amp;#x2019;s price to the customer is fixed or determinable and
 collectability is reasonably assured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has entered into license agreements to develop,
 manufacture and commercialize drug products. The terms of these
 agreements typically contain multiple elements, including licenses
 and research and development services. Payments to the Company
 under these agreements may include nonrefundable license fees,
 payments for research activities, payments based upon the
 achievement of certain milestones and royalties on any resulting
 net product sales. There are no performance, cancellation,
 termination or refund provisions in any of the arrangements that
 contain material financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company records revenue related to these agreements in
 accordance with ASC 605-25, &lt;i&gt;Revenue Recognition Multiple-Element
 Arrangements&lt;/i&gt;. In order to account for these agreements, the
 Company identifies the deliverables included within the arrangement
 and evaluates which deliverables represent separate units of
 accounting based on whether certain criteria are met, including
 whether the delivered element has stand-alone value to the
 counterparty. The consideration received is then allocated among
 the separate units of accounting based on each unit&amp;#x2019;s
 relative selling price. The identification of individual elements
 in a multiple-element arrangement and the estimation of the selling
 price of each element involve significant judgment, including
 consideration as to whether each delivered element has standalone
 value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Arrangement consideration allocated to license deliverables that
 represent separate units of accounting are recognized as revenue at
 the outset of the agreement assuming the general criteria for
 revenue recognition noted above have been met. Arrangement
 consideration allocated to license deliverables that do not
 represent separate units of accounting are deferred. The Company
 has determined that its license deliverables represent separate
 units of accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Arrangement consideration allocated to research and development
 services that represent separate units of accounting are recognized
 as the services are performed, assuming the general criteria for
 revenue recognition noted above have been met. The Company has
 determined that its research and developments services
 deliverables, as applicable, represent separate units of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Maruishi Pharmaceutical Co., Ltd.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In April 2013, the Company entered into a license agreement with
 Maruishi Pharmaceutical Co., Ltd. (&amp;#x201C;Maruishi&amp;#x201D;) under
 which the Company granted Maruishi an exclusive license to develop,
 manufacture, and commercialize drug products containing CR845 for
 acute pain and uremic pruritus in Japan. The Company and Maruishi
 are responsible to use commercially reasonable efforts, at its
 expense, to develop, obtain regulatory approval for and
 commercialize CR845 in the United States and Japan, respectively.
 In addition, the Company will provide Maruishi specific clinical
 development services for CR845 used in Maruishi&amp;#x2019;s field of
 use. Under the terms of the agreement, the Company received an
 upfront non-refundable, non-creditable license fee of $15,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The Company has identified two deliverables under ASC 605-25:
 (1)&amp;#xA0;the license; and (2)&amp;#xA0;the R&amp;amp;D services specific to
 the uremic pruritus field of use. The Company has determined that
 the license has standalone value because Maruishi has the right to
 sublicense and manufacture CR845 in Japan. The second deliverable
 is the R&amp;amp;D services, which also have standalone value as
 similar services are sold separately by other vendors. Since both
 the license and the R&amp;amp;D services separability criteria have
 been met, they are being accounted for as separate units of
 accounting at the outset of the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Along with the R&amp;amp;D services performed by the Company for
 Maruishi, the Company supplies Maruishi with CR845 clinical
 material as an accommodation. The Company has entered into
 manufacturing and service agreements with third parties to
 manufacture CR845. Payments made by the Company to third parties
 based on firm and fixed commitments by Maruishi to purchase CR845
 from the Company are capitalized as prepaid expense. During the
 manufacturing process, title and risk of loss remains with the
 third party until the Company has paid in full for the
 material.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 Once the Company has title to the CR845 and has delivered it to
 Maruishi, prepaid expense related to that CR845 is reduced with an
 offset to R&amp;amp;D expense. At that time, Maruishi reimburses the
 Company for its external and internal costs for purchasing CR845
 and processing the sale to Maruishi and the Company recognizes
 collaborative revenue for the reimbursement amount. Deposits
 received from Maruishi prior to delivery of CR845 are recorded as
 deferred revenue.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of March&amp;#xA0;31, 2014 and December&amp;#xA0;31, 2013, the Company
 had deferred $3,417 and $3,475, respectively, of R&amp;amp;D service
 revenue related to the Maruishi collaboration. During the three
 months ended March&amp;#xA0;31, 2014, the Company recognized $178 of
 R&amp;amp;D service revenue, including $151 of amortization of deferred
 revenue from the upfront payment received pursuant to the license
 agreement with Maruishi and $27 from the sale of CR845 clinical
 compound.&lt;/p&gt;
 &lt;/div&gt;</cara:RevenueRecognitionTextBlock>
  <cara:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="pure" decimals="2" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_3_5">0.20</cara:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
  <cara:EmploymentAgreementRenewalTerm contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_1F3A7AF4-0739-468C-9716-783445DD7409_1_2">P1Y</cara:EmploymentAgreementRenewalTerm>
  <cara:NonCashCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_3">353000</cara:NonCashCompensationExpense>
  <cara:NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_24">1465000</cara:NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering>
  <cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_13">-3383000</cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <cara:DeferredRentLiabilityBenefit contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_6">65000</cara:DeferredRentLiabilityBenefit>
  <cara:ConvertiblePreferredStockDisclosureTextBlock contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" id="id_4942281_8F4EFC27-78F9-4AF4-9B61-AAB4D2B4FC31_1_0">&lt;div&gt;
 &lt;table width="100%" style="font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0"&gt;
 &lt;tr&gt;
 &lt;td width="4%" align="left" valign="top"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Convertible Preferred
 Stock&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;
 As of December&amp;#xA0;31, 2013, the Company had authorized an
 aggregate of 29,402,200 shares of convertible preferred stock, par
 value $0.001 per share. Upon the closing of the Company&amp;#x2019;s IPO
 on February&amp;#xA0;5, 2014, all 29,186,929 shares of the
 Company&amp;#x2019;s convertible preferred stock that were issued and
 outstanding on that date were automatically converted into an
 aggregate of 12,554,171 shares of its common stock. As of
 March&amp;#xA0;31, 2014, there were no shares of convertible preferred
 stock authorized or outstanding.&lt;/p&gt;
 &lt;/div&gt;</cara:ConvertiblePreferredStockDisclosureTextBlock>
  <cara:AmortizationOfDeferredRevenue contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_137C6D80-29BD-4918-B058-E62F1B5E203C_1_2">151000</cara:AmortizationOfDeferredRevenue>
  <cara:NoncashOrPartNoncashUnpaidInitialPublicOfferingIssuanceCosts contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_25">60000</cara:NoncashOrPartNoncashUnpaidInitialPublicOfferingIssuanceCosts>
  <cara:ResearchAndDevelopmentServiceRevenue contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_137C6D80-29BD-4918-B058-E62F1B5E203C_1_1">178000</cara:ResearchAndDevelopmentServiceRevenue>
  <cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_4942281_84071DF4-7ED9-47D7-8FC1-6E9792CF6201_1_15">-0.22</cara:NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare>
  <cara:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_A96458E8-E57C-41CC-A366-67800FA174C5_1_17">57772000</cara:ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid>
  <cara:PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="pure" decimals="2" id="id_4942281_73431ED6-0D47-45B7-9487-7644D210DE88_1_0">0.65</cara:PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash>
  <cara:StockIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingCosts contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9005_17">7003000</cara:StockIssuanceCostsUnderwritingDiscountsCommissionsAndOfferingCosts>
  <cara:RevenueRecognizedFromSaleOfClinicalCompound contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0" unitRef="iso4217_USD" decimals="-3" id="id_4942281_137C6D80-29BD-4918-B058-E62F1B5E203C_1_3">27000</cara:RevenueRecognizedFromSaleOfClinicalCompound>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x923140" unitRef="pure" decimals="4" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_2_0">0.0272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x923140" unitRef="pure" decimals="2" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_2_1">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x923140_930809x1258850" id="id_4942281_A6F61293-D7B3-4CF8-B54F-E2F5CDEDFBF5_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x932953" unitRef="pure" decimals="4" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_1_0">0.0219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x932953" unitRef="pure" decimals="2" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_1_1">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:NetIncomeLoss contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x929313" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9004_19">-3383000</us-gaap:NetIncomeLoss>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9001_13">12554171</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x930643" unitRef="shares" decimals="INF" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9001_15">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9001_14">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x930643" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9001_12">13000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932377" unitRef="shares" decimals="INF" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_9001_12">-29186929</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932377" unitRef="iso4217_USD" decimals="-3" id="id_4942281_2DF9D1C9-C606-4176-A991-7AFAFA09115E_9001_11">-65586000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9003_14">56241000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9003_12">65573000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932586" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0E9F89A6-A5BF-4EA4-9BAC-88A56ED6C8D9_9003_18">-353000</us-gaap:ShareBasedCompensation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_928305x926520" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_2001_1">877160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_928305x929614" unitRef="shares" decimals="INF" id="id_4942281_C87E98EB-AF42-41F1-A40E-3191C4148801_3001_2">19851</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x1252239" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0C026780-9380-40CB-8732-7EF7BBE9CF17_1001_0">219000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x924898" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_1003_3">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x975410" id="id_4942281_D54EACD5-A796-4F79-86E1-6A85D7BBBB47_2003_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x975410" unitRef="iso4217_USD" decimals="-3" id="id_4942281_0C026780-9380-40CB-8732-7EF7BBE9CF17_2001_1">134000</us-gaap:AllocatedShareBasedCompensationExpense>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x975410">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cara:NonEmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_929038x1252239">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cara:EmployeeAndNonEmployeeDirectorStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_928305x926520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x923140_930809x1258850">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_929038x975410">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cara:NonEmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_929038x1252239">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cara:EmployeeAndNonEmployeeDirectorStockOptionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x926520">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_928305x926173">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0_927592x924725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_90_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_365_20131231_0_930809x1258850">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_365_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_2_20140130_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2014-01-29</startDate>
      <endDate>2014-01-30</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_2_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2014-03-30</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_2_20140205_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <startDate>2014-02-04</startDate>
      <endDate>2014-02-05</endDate>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140130_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2014-01-30</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140116_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2014-01-16</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_930809x1083036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_927592x924725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_926956x932359_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0_926956x927254_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0_927592x924725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_930809x1258850">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_930809x1083036">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_927592x924725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_926956x932359_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_926956x927254_928472x926284_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1119542">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">cara:OperatingLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_926751x1113202">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">cara:EmploymentAgreementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0_926437x923140_930809x1258850">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cara:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x932586">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x932377">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x930643">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x929313">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0_927592x924725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2013-03-31</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20130430_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2013-04-30</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140505_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2014-05-05</instant>
    </period>
  </context>
  <context id="eol_PE693401--1410-Q0003_STD_0_20140205_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001346830</identifier>
    </entity>
    <period>
      <instant>2014-02-05</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Officers">
    <measure>cara:Officers</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
</xbrl>
